Literature DB >> 22793372

Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.

Yiu-Yin Cheung1, Haibo Yu, Kaiping Xu, Beiyan Zou, Meng Wu, Owen B McManus, Min Li, Craig W Lindsley, Corey R Hopkins.   

Abstract

A potent and selective inhibitor of KCNQ2, (S)-5 (ML252, IC(50) = 69 nM), was discovered after a high-throughput screen of the MLPCN library was performed. SAR studies revealed a small structural change (ethyl group to hydrogen) caused a functional shift from antagonist to agonist activity (37, EC(50) = 170 nM), suggesting an interaction at a critical site for controlling gating of KCNQ2 channels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22793372      PMCID: PMC3530927          DOI: 10.1021/jm300700v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Cholinergic drugs in pharmacotherapy of Alzheimer's disease.

Authors:  P Camps; D Muñoz-Torrero
Journal:  Mini Rev Med Chem       Date:  2002-02       Impact factor: 3.862

2.  Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener.

Authors:  Haibo Yu; Meng Wu; Steven D Townsend; Beiyan Zou; Shunyou Long; J Scott Daniels; Owen B McManus; Min Li; Craig W Lindsley; Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

3.  Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.

Authors:  R Zaczek; R J Chorvat; J A Saye; M E Pierdomenico; C M Maciag; A R Logue; B N Fisher; D H Rominger; R A Earl
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

4.  Strategic use of plasma and microsome binding to exploit in vitro clearance in early drug discovery.

Authors:  George Chang; Stefanus J Steyn; John P Umland; Dennis O Scott
Journal:  ACS Med Chem Lett       Date:  2010-02-03       Impact factor: 4.345

5.  The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels.

Authors:  Heun Soh; Anastassios V Tzingounis
Journal:  Mol Pharmacol       Date:  2010-09-15       Impact factor: 4.436

6.  Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers.

Authors:  H J Pieniaszek; W D Fiske; T D Saxton; Y S Kim; D M Garner; M Xilinas; R Martz
Journal:  J Clin Pharmacol       Date:  1995-01       Impact factor: 3.126

7.  2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.

Authors:  R A Earl; R Zaczek; C A Teleha; B N Fisher; C M Maciag; M E Marynowski; A R Logue; S W Tam; W J Tinker; S M Huang; R J Chorvat
Journal:  J Med Chem       Date:  1998-11-05       Impact factor: 7.446

8.  Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.

Authors:  Manthena V S Varma; R Scott Obach; Charles Rotter; Howard R Miller; George Chang; Stefanus J Steyn; Ayman El-Kattan; Matthew D Troutman
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

  8 in total
  10 in total

1.  Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.

Authors:  Hai-bo Yu; Bei-yan Zou; Xiao-liang Wang; Min Li
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

Review 2.  High throughput screening technologies for ion channels.

Authors:  Hai-bo Yu; Min Li; Wei-ping Wang; Xiao-liang Wang
Journal:  Acta Pharmacol Sin       Date:  2015-12-14       Impact factor: 6.150

Review 3.  Drugs for allosteric sites on receptors.

Authors:  Cody J Wenthur; Patrick R Gentry; Thomas P Mathews; Craig W Lindsley
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-02       Impact factor: 13.820

4.  Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitors.

Authors:  Wandong Wen; Wenjun Wu; Ian M Romaine; Kristian Kaufmann; Yu Du; Gary A Sulikowski; C David Weaver; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2013-06-20       Impact factor: 2.823

5.  Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels.

Authors:  Hai-Ning Hu; Ping-Zheng Zhou; Fei Chen; Min Li; Fa-Jun Nan; Zhao-Bing Gao
Journal:  Acta Pharmacol Sin       Date:  2013-08-12       Impact factor: 6.150

6.  An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.

Authors:  Jacob D Porter; Oscar Vivas; C David Weaver; Abdulmohsen Alsafran; Elliot DiMilo; Leggy A Arnold; Eamonn J Dickson; Chris Dockendorff
Journal:  Bioorg Med Chem Lett       Date:  2019-09-14       Impact factor: 2.823

Review 7.  Chemical modulation of Kv7 potassium channels.

Authors:  Matteo Borgini; Pravat Mondal; Ruiting Liu; Peter Wipf
Journal:  RSC Med Chem       Date:  2021-01-14

Review 8.  2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.

Authors:  Craig W Lindsley
Journal:  J Med Chem       Date:  2014-09-15       Impact factor: 7.446

9.  TRPM4 mediates a subthreshold membrane potential oscillation in respiratory chemoreceptor neurons that drives pacemaker firing and breathing.

Authors:  Keyong Li; Stephen B G Abbott; Yingtang Shi; Pierce Eggan; Elizabeth C Gonye; Douglas A Bayliss
Journal:  Cell Rep       Date:  2021-02-02       Impact factor: 9.423

10.  KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.

Authors:  Nissi Varghese; Anna Lauritano; Maurizio Taglialatela; Anastasios V Tzingounis
Journal:  J Neurophysiol       Date:  2021-03-17       Impact factor: 2.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.